changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Please find below a list of our press releases.
8 Jan 2019
Distributed ledger technology is a game changer for managing stock levels of critical antidote.
21 Dec 2018
An estimated 500 patients per year in France could be eligible for treatment with TheraSphere®
3 Dec 2018
BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter. The BTG Sentry filter is designed to provide protection from Pulmonary Embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, eliminating the need to retrieve and addressing the typical filter-related complications associated with conventional IVC filters.
20 Nov 2018
Recommended Cash Offer for BTG plc by Boston Scientific Corporation
13 Nov 2018
BTG plc (LSE: BTG), the global healthcare company, today announces its Interim Results for the six months ended 30 September 2018.
7 Nov 2018
BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of the two-year results for the SENTRY trial, at the Vascular Interventional Advances (VIVA) conference in Las Vegas. The prospective, multicenter trial of the BTG Sentry, the world’s first bioconvertible IVC filter, found that in addition to providing protection against pulmonary embolism (PE) during the transient risk period, the device also had zero instances of tilt, perforation, migration and embolization through two years of imaging-intensive follow-up.
6 Nov 2018
BTG plc (LSE: BTG), the global healthcare company, announced today that the first EKOS™ CU 4.0 units have been shipped from BTG’s facility in Bothell (Washington, US) to Europe, where full commercial launch will begin. New features of the EKOS™ CU 4.0 include an interactive colour touchscreen, a built-in battery and separate ports for managing two EKOS™ devices simultaneously.
4 Oct 2018
Good first half performance, updating full year sales growth guidance
BTG plc (LSE: BTG), the global healthcare company, provides the following update for the six months ended 30 September 2018.
BTG plc (LSE: BTG), the global healthcare company, announces that Garry Watts has informed the Board that he wishes to retire as Chairman and Non-executive Director of the Company. The Board has commenced a process to appoint a successor to Mr Watts, who will continue as Chairman until 31 December 2018.
26 Sep 2018
BTG plc (LSE: BTG) today announced a policy for replacement of expired vials of CroFab® Crotalidae Polyvalent Immune Fab (Ovine), allowing customers to return the product for replacement up to 90 days after expiration. This change goes into effect immediately, and provides CroFab®customers with a process for replacing their expired product at no charge. CroFab® is the only available FDA-approved product for the management of all North American pit viper envenomations in adult and pediatric patients.1